1. Home
  2. IAUX vs CRVS Comparison

IAUX vs CRVS Comparison

Compare IAUX & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo i-80 Gold Corp.

IAUX

i-80 Gold Corp.

HOLD

Current Price

$1.36

Market Cap

1.3B

Sector

N/A

ML Signal

HOLD

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

HOLD

Current Price

$13.18

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IAUX
CRVS
Founded
2020
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.1B
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
IAUX
CRVS
Price
$1.36
$13.18
Analyst Decision
Buy
Strong Buy
Analyst Count
1
6
Target Price
$1.50
$30.17
AVG Volume (30 Days)
9.5M
1.2M
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
11.76
48.04
EPS
N/A
N/A
Revenue
$95,193,000.00
N/A
Revenue This Year
$132.25
N/A
Revenue Next Year
$89.76
N/A
P/E Ratio
N/A
N/A
Revenue Growth
89.12
N/A
52 Week Low
$0.55
$3.96
52 Week High
$2.24
$26.95

Technical Indicators

Market Signals
Indicator
IAUX
CRVS
Relative Strength Index (RSI) 46.13 40.96
Support Level $1.23 $12.95
Resistance Level $1.54 $14.00
Average True Range (ATR) 0.07 0.79
MACD 0.01 -0.27
Stochastic Oscillator 51.06 1.17

Price Performance

Historical Comparison
IAUX
CRVS

About IAUX i-80 Gold Corp.

i-80 Gold Corp is a well-financed gold and silver producer engaged in the exploration, development, and production of gold, silver, and poly-metallic deposits. The Company's principal assets include the Ruby Hill Mine, Lone Tree Mine, Granite Creek Mine, and McCoy-Cove Project.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Share on Social Networks: